Dissecting the PI3K signaling axis in pediatric solid tumors: Novel targets for clinical integration

Frontiers in Oncology

Volumn 3 APR, Issue , 2013, Pages

  Loh, Amos H P ^a   Brennan, Rachel C ^a   Lang, Walter H ^a   Hickey, Robert J ^b   Malkas, Linda H ^b   Sandoval, John A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Akt; MTOR; Pediatric solid tumors; PI3K

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 8 [4 (1 AMINOCYCLOBUTYL) PHENYL] 9 PHENYL 1, 2, 4 TRIAZOLO [3, 4 F] [1, 6] NAPHTHYRIDIN 3 (2H) ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALENDRONIC ACID; BUPARLISIB; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DACTOLISIB; DALOTUZUMAB; DOXORUBICIN; ENZASTAURIN; ETOPOSIDE; EVEROLIMUS; IRINOTECAN; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAPAMYCIN; RIDAFOROLIMUS; TEMOZOLOMIDE; TEMSIROLIMUS; TOPOTECAN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; WORTMANNIN;

APOPTOSIS; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CHILD; CHILDHOOD CANCER; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME INHIBITION; EWING SARCOMA; FEBRILE NEUTROPENIA; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; MUCOSA INFLAMMATION; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOSARCOMA; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 84890722396     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00093     Document Type: Review

References (78)

1. Ayalon, D., Glaser, T., and Werner, H. (2001). Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm. IGF Res. 11, 289-297.
2. Banno, Y., Takuwa, Y., Akao, Y., Okamoto, H., Osawa, Y., Naganawa, T., et al. (2001). Involvement of phospholipase D in sphingosine 1-phosphate-induced activation of phosphatidylinositol 3-kinase and Akt in Chinese hamster ovary cells overexpressing EDG3. J. Biol. Chem. 276, 35622-35628.
3. Barrett, D., Brown, V. I., Grupp, S. A., and Teachey, D. T. (2012). Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr. Drugs 14, 299-316.
4. Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., et al. (2012). Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 30, 282-290.
5. Benini, S., Manara, M. C., Cerisano, V., Perdichizzi, S., Strammiello, R., Serra, M., et al. (2004). Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. Int. J. Cancer 108, 358-366.
6. Biggs, W. H. III, Meisenhelder, J., Hunter, T., Cavenee, W. K., and Arden, K. C. (1999). Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl. Acad. Sci. U.S.A. 96, 7421-7426.
7. Brachmann, S. M., Hofmann, I., Schnell, C., Fritsch, C., Wee, S., Lane, H., et al. (2009). Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 106, 22299-22304.
8. Brown, R. E., Tan, D., Taylor, J. S., Miller, M., Prichard, J. W., and Kott, M. M. (2007). Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in high risk neuro-blastoma, with cell cycle and protein analyte correlates. Ann. Clin. Lab. Sci. 37, 141-147.
9. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., et al. (1999). Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96, 857-868.
10. Calne, R. Y., Collier, D. S., Lim, S., Pollard, S. G., Samaan, A., White, D. J., et al. (1989). Rapamycin for immunosuppression in organ allografting. Lancet 2, 227.
11. Carnero, A. (2010). The PKB/AKT pathway in cancer. Curr. Pharm. Des. 16, 34-44.
12. Cen, L., Arnoczky, K. J., Hsieh, F. C., Lin, H. J., Qualman, S. J., Yu, S., et al. (2007). Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Mod. Pathol. 20, 936-946.
13. Charytonowicz, E., Matushansky, I., Doménech, J. D., Castillo-Martín, M., Ladanyi, M., Cordon-Cardo, C., et al. (2012). PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation. Clin. Transl. Oncol. 14, 197-206.
14. Chow, L. M., and Baker, S. J. (2006). PTEN function in normal and neoplastic growth. Cancer Lett. 241, 184-196.
15. Choy, E., Hornicek, F., MacConaill, L., Harmon, D., Tariq, Z., Garraway, L., et al. (2012). High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer 118, 2905-2914.
16. Dam, V., Morgan, B. T., Mazanek, P., and Hogarty, M. D. (2006). Mutations in PIK3CA are infrequent in neuroblastoma. BMC Cancer 6:177. doi:10.1186/1471-2407-6-177
17. de Alava, E., and Gerald, W. L. (2000). Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J. Clin. Oncol. 18, 204-213.
18. Delbaldo, C., Albert, S., Dreyer, C., Sablin, M. P., Serova, M., Raymond, E., et al. (2011). Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors. Target. Oncol. 6, 119-124.
19. Engelman, J. A. (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550-562.
20. Federico, S. M. (2012). Comprehensive preclinical testing for neuroblastoma using orthotopic xenografts of a patient tumor. J. Clin. Oncol. 30(Suppl.), e13584. [Abstract].
21. Fine, H. A., Kim, L., Albert, P. S., Duic, J. P., Ma, H., Zhang, W., et al. (2005). Results from phase II trial of Enzastaurin (LY317615) in patients with recurrent high grade gliomas. J. Clin. Oncol. 23, 115s. [Abstract].
22. Fouladi, M., Laningham, F., Wu, J., O'Shaughnessy, M. A., Molina, K., Broniscer, A., et al. (2007). Phase I study of everolimus in pediatric patients with refractory solid tumors. J. Clin. Oncol. 25, 4806-4812.
23. Freeman, S. S., Allen, S. W., Ganti, R., Wu, J., Ma, J., Su, X., et al. (2008). Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 113, 1453-1461.
24. Geoerger, B., Kieran, M. W., Grupp, S., Perek, D., Clancy, J., Krygowski, M., et al. (2012). Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur. J. Cancer 48, 253-262.
25. Gibbs, C. P., Kukekov, V. G., Reith, J. D., Tchigrinova, O., Suslov, O. N., Scott, E. W., et al. (2005). Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7, 967-976.
26. Gong, C., Liao, H., Wang, J., Lin, Y., Qi, J., Qin, L., et al. (2012). LY294002 induces G0/G1 cell cycle arrest and apoptosis of cancer stem-like cells from human osteosarcoma via down-regulation of PI3K activity. Asian Pac. J. Cancer Prev. 13, 3103-3107.
27. Hartford, C. M., Desai, A. A., Janisch, L., Karrison, T., Rivera, V. M., Berk, L., et al. (2009). A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin. Cancer Res. 15, 1428-1434.
28. Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., and Mills, G. B. (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4, 988-1004.
29. Hotfilder, M., Sondermann, P., Senss, A., van Valen, F., Jürgens, H., and Vormoor, J. (2005). PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death. Br. J. Cancer 92, 705-710.
30. Inoue, R., Matsuki, N. A., Jing, G., Kanematsu, T., Abe, K., and Hirata, M. (2005). The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. Br. J. Pharmacol. 146, 633-641.
31. Izycka-Swieszewska, E., Drozynska, E., Rzepko, R., Kobierska-Gulida, G., Grajkowska, W., Perek, D., et al. (2010). Analysis of PI3K/AKT/mTOR signalling pathway in high risk neuroblastic tumours. Pol. J. Pathol. 61, 192-198.
32. Jiang, B. H., Aoki, M., Zheng, J. Z., Li, J., and Vogt, P. K. (1999). Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. Proc. Natl. Acad. Sci. U.S.A. 96, 2077-2081.
33. Jiang, B. H., and Liu, L. Z. (2008). PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim. Biophys. Acta 1784, 150-158.
34. Johnsen, J. I., Segerström, L., Orrego, A., Elfman, L., Henriksson, M., Kågedal, B., et al. (2008). Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 27, 2910-2922.
35. Kaliman, P., Viñals, F., Testar, X., Palacín, M., and Zorzano, A. (1996). Phosphatidylinositol 3-kinase inhibitors block differentiation of skeletal muscle cells. J. Biol. Chem. 271, 19146-19151.
36. Kamura, S., Matsumoto, Y., Fukushi, J. I., Fujiwara, T., Iida, K., Okada, Y., et al. (2010). Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway. Br. J. Cancer 103, 370-381.
37. Koul, D., Fu, J., Shen, R., LaFortune, T. A., Wang, S., Tiao, N., et al. (2012). Antitumor activity of NVP-BKM120-a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin. Cancer Res. 18, 184-195.
38. Krueger, D. A., Care, M. M., Holland, K., Agricola, K., Tudor, C., Mangeshkar, P., et al. (2010). Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363, 1801-1811.
39. Kulik, G., Klippel, A., and Weber, M. J. (1997). Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol. 17, 1595-1606.
40. Laguë, M. N., Paquet, M., Fan, H. Y., Kaartinen, M. J., Chu, S., Jamin, S. P., et al. (2008). Synergistic effects of PTEN loss and WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and progression. Carcinogenesis 29, 2062-2072.
41. Lau, C. C., Harris, C. P., Lu, X. Y., Perlaky, L., Gogineni, S., Chintagumpala, M., et al. (2004). Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 39, 11-21.
42. Li, H. G., Wang, Q., Li, H. M., Kumar, S., Parker, C., Slevin, M., et al. (2007). PAX3 and PAX3-FKHR promote rhabdomyosarcoma cell survival through downregulation of PTEN. Cancer Lett. 253, 215-223.
43. Li, Y., Jiang, B., Ensign, W. Y., Vogt, P. K., and Han, J. (2000). Myogenic differentiation requires signalling through both phosphatidylinositol 3-kinase and p38 MAP kinase. Cell. Signal. 12, 751-757.
44. Li, Z., Oh, D. Y., Nakamura, K., and Thiele, C. J. (2011). Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo. Cancer 117, 5412-5422.
45. Li, Z., Tan, F., Liewehr, D. J., Steinberg, S. M., and Thiele, C. J. (2010). In vitro and in vivo inhibition of neuroblastoma tumor cell growth by Akt inhibitor perifosine. J. Natl. Cancer Inst. 102, 758-770.
46. Li, Z., Yan, S., Attayan, N., Ramalingam, S., and Thiele, C. J. (2012). Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma. Clin. Cancer Res. 18, 3603-3615.
47. Ligresti, G., Militello, L., Steelman, L. S., Cavallaro, A., Basile, F., Nicoletti, F., et al. (2009). PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 8, 1352-1358.
48. Liu, L., Chen, L., Chung, J., and Huang, S. (2008). Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene 27, 4998-5010.
49. Maira, S. M. (2011). PI3K inhibitors for cancer treatment: five years of preclinical and clinical research after BEZ235. Mol. Cancer Ther. 10, 2016.
50. Maira, S. M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., et al. (2008). Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863.
51. Man, T. K., Lu, X. Y., Jaeweon, K., Perlaky, L., Harris, C. P., Shah, S., et al. (2004). Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 4:45. doi:10.1186/1471-2407-4-45
52. Minniti, C. P., Luan, D., O'Grady, C., Rosenfeld, R. G., Oh, Y., and Helman, L. J. (1995). Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. Cell Growth Differ. 6, 263-269.
53. Moriceau, G., Ory, B., Mitrofan, L., Riganti, C., Blanchard, F., Brion, R., et al. (2010). Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res. 70, 10329-10339.
54. Muñoz, J., Lázcoz, P., Inda, M. M., Nistal, M., Pestaña, A., Encío, I. J., et al. (2004). Homozygous deletion and expression of PTEN and DMBT1 in human primary neuroblastoma and cell lines. Int. J. Cancer 109, 673-679.
55. Naing, A., Kurzrock, R., Burger, A., Gupta, S., Lei, X., Busaidy, N., et al. (2011). Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin. Cancer Res. 17, 6052-6060.
56. Opel, D., Poremba, C., Simon, T., Debatin, K. M., and Fulda, S. (2007). Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res. 67, 735-745.
57. Pantuck, A. J., Seligson, D. B., Klatte, T., Yu, H., Leppert, J. T., Moore, L., et al. (2007). Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109, 2257-2267.
58. Párrizas, M., Saltiel, A. R., and LeRoith, D. (1997). Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways. J. Biol. Chem. 272, 154-161.
59. Pressey, J. G., Wright, J. M., Geller, J. I., Joseph, D. B., Pressey, C. S., and Kelly, D. R. (2010). Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr. Blood Cancer 54, 1035-1037.
60. Qiao, J., Kang, J., Cree, J., Evers, B. M., and Chung, D. H. (2005). Gastrin-releasing peptide-induced down-regulation of tumor suppressor protein PTEN (phosphatase and tensin homolog deleted on chromosome ten) in neuroblastomas. Ann. Surg. 241, 684-692.
61. Richardson, P. G., Eng, C., Kolesar, J., Hideshima, T., and Anderson, K. C. (2012). Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin. Drug Metab. Toxicol. 8, 623-633.
62. Samuels, Y., and Ericson, K. (2006). Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18, 77-82.
63. Sehgal, S. N., Baker, H., and Vezina, C. (1975). Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. 28, 727-732.
64. Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J., Valero, V., Guzman, M., et al. (2008). NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68, 8022-8030.
65. Shapiro, D. N., Sublett, J. E., Li, B., Downing, J. R., and Naeve, C. W. (1993). Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res. 53, 5108-5112.
66. Spunt, S. L., Grupp, S. A., Vik, T. A., Santana, V. M., Greenblatt, D. J., Clancy, J., et al. (2011). Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J. Clin. Oncol. 29, 2933-2940.
67. Tapscott, S. J., Thayer, M. J., and Weintraub, H. (1993). Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science 259, 1450-1453.
68. Thornton, K. A., Chen, A. R., Trucco, M. M., Shah, P., Wilky, B. A., Gul, N., et al. (2013). A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int. J. Cancer. doi:10.1002/ijc.28083
69. Toretsky, J. A., Kalebic, T., Blakesley, V., LeRoith, D., and Helman, L. J. (1997). The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J. Biol. Chem. 272, 30822-30827.
70. Toretsky, J. A., Thakar, M., Eskenazi, A. E., and Frantz, C. N. (1999). Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. Cancer Res. 59, 5745-5750.
71. Tsubaki, M., Satou, T., Itoh, T., Imano, M., Ogaki, M., Yanae, M., et al. (2012). Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. Toxicol. Appl. Pharmacol. 259, 402-410.
72. Wagner, M. J., and Maki, R. G. (2013). Type-1 insulin like growth factor receptor targeted therapies in pediatric cancer. Front. Oncol. 3:9. doi:10.3389/fonc.2013.00009
73. Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L. M., et al. (2010). Phase III study of Enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 28, 1168-1174.
74. Yamamoto, T., Ohno, T., Wakahara, K., Nagano, A., Kawai, G., Saitou, M., et al. (2009). Simultaneous inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways augment the sensitivity to actinomycin D in Ewing sarcoma. J. Cancer Res. Clin. Oncol. 135, 1125-1136.
75. Yu, H. G., Ai, Y. W., Yu, L. L., Zhou, X. D., Liu, J., Li, J. H., et al. (2008). Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int. J. Cancer 122, 433-443.
76. Zeng, M., and Zhou, J. N. (2008). Roles of autophagy and mTOR signaling in neuronal differentiation of mouse neuroblastoma cells. Cell. Signal. 20, 659-665.
77. Zeng, Z., Shi, Y. X., Tsao, T., Qiu, Y., Kornblau, S. M., Baggerly, K. A., et al. (2012). Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood 120, 2679-2689.
78. Zhang, J., Hu, S., Schofield, D. E., Sorensen, P. H., and Triche, T. J. (2004). Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas. Cancer Res. 64, 6026-6034.